Frequently Asked Questions (FAQs)

PREMARIN is indicated in the treatment of moderate to severe vasomotor symptoms due to menopause, treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, and the prevention of postmenopausal osteoporosis.1
When prescribing solely for the symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered.1
When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medications should be carefully considered.1
PREMARIN contains a mixture of conjugated estrogens, which are a mixture of sodium estrone sulfate and sodium equilin sulfate and other components, including sodium sulfate conjugates, 17α-dihydroequilin, 17α-estradiol, and 17ß-dihydroequilin.1
This is not a comprehensive list of ingredients.
PREMARIN is available in 5 dosage strengths (range spans from 0.3 mg to 1.25 mg).1
Estrogens, with or without progestins, should be prescribed at the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman. In some cases, hysterectomized women with a history of endometriosis may need a progestin.
PREMARIN should not be used in women with any of the following conditions: undiagnosed abnormal genital bleeding; known, suspected, or a history of breast cancer; known or suspected estrogen-dependent neoplasia; active deep vein thrombosis, pulmonary embolism, or a history of these conditions; active arterial thromboembolic disease (eg, stroke, myocardial infarction), or a history of these conditions; anaphylactic reaction or angioedema with PREMARIN; liver impairment or disease; thrombophilic disorders; known or suspected pregnancy.1
Estrogens increase the risk of gallbladder disease. Discontinue estrogen if loss of vision, severe hypercalcemia, severe hypertriglyceridemia or cholestatic jaundice occurs. Monitor thyroid function in women on thyroid replacement therapy, because estrogens may be associated with increased thyroid binding globulin (TBG) levels.1
Most common adverse reactions (≥5%) are abdominal pain, asthenia, pain, back pain, headache, flatulence, nausea, depression, insomnia, breast pain, endometrial hyperplasia, leucorrhea, vaginal hemorrhage, and vaginitis.1
Yes. With the PREMARIN Savings Card, eligible patients may:
  • Pay as little as $30 for their prescription*
  • Save up to $55 per 30-day prescription or $165 for a 90-day prescription
  • Use this offer up to 12 times per calendar year
Download savings cards for your patients here.
*Terms and Conditions apply. This Card is not health insurance. This Card is only accepted at participating pharmacies. No membership fees are associated with this Card. Eligible patients will pay as little as $30 with a savings of up to $55 per prescription filled. Limit 12 offers per calendar year. Maximum savings of $660 per calendar year. If you are enrolled in a state or federally funded prescription insurance program, you may not use the savings card even if you elect to be processed as an uninsured (cash-paying) patient. Exp. 12/31/21. See below for full Terms and Conditions. For help processing, please call 1-855-477-7309. Pfizer: Attn: PREMARIN, 235 East 42nd Street, New York, NY 10017,

The majority of commercially insured patients have unrestricted access to PREMARIN.2

Greater than 55% commercial patients.
Unrestricted access is not subject to prior authorization or step edit. National access based on MMIT data as of September 2020. Please confirm each patient's coverage with their plan. No safety or efficacy conclusions can be drawn from these data. 
  1. Premarin [prescribing information]. New York, NY: Pfizer Inc.; September 2018.
  2. Data on file. Pfizer Inc., New York, NY.